The ethics of conducting psychosis‐inducing experiments

References

• Justice Edward Greenfield, opening statement of his decision, TD v NYS OMH, 626 N.Y.S. 2d 1015 (Sup. Ct. NY County 1995).
   Google Scholar
• Katz , J. “Human experimentation and human rights,” . Health Law Symposium, St. Louis University Law Journal , 1993 ( 38 ) 7 – 54 .
   Google Scholar
• Abelson , J.L. and Nesse , R.M. 1994 . “Pentagastrin infusions in patients with panic disorder: I. Symptoms and cardiovascular responses,” . Biological Psychiatry , 36 : 73 – 83 .
   Google Scholar
• Abi‐Dargham , A. , Gil , R. , Krystal , J. , Baldwin , R.M. , Seibyl , J.P. , Bowers , M. , van Dyck , C.H. , Charney , D.S. , Innis , R.B. and Laruelle , M. 1998 . “Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort,” . American Journal of Psychiatry , 155 : 761 – 767 .
   PubMed Web of Science ®Google Scholar
• Angrist , B.M. and Gershon , S. 1970 . “The phenomenology of experimentally induced amphetamine psychosis: preliminary observations . Biological Psychiatry , 2 : 95 – 107 .
   PubMedGoogle Scholar
• Angrist , B.M. , Peslow , E. , Rubinstein , M. , Wolkin , A. and Rotrosen , J. 1985 . “Amphetamine response and relapse risk after depot neuroleptic discontinuation,” . Psychopharmacology, (Berl) , 85 : 277 – 283 .
   PubMed Web of Science ®Google Scholar
• Breier , A. , Malhotra , A.K. , Pinals , D.A. , Weisenfeld , N.I. and Pickar , D. 1997a . “Association of ketamine‐induced psychosis with focal activation of the prefrontal cortex in healthy volunteers,” . American Journal of Psychiatry , 154 : 805 – 811 .
   PubMed Web of Science ®Google Scholar
• Breier , A. Su , Daunders , Carson , Kolachana , de Bartolomeis , Weinberger , D. , Weisenfeld , N.I. , Malhotra , Eckleman A.K. and Pickar , D. 1997b . “Schizophrenia is associated with elevated amphetamine‐induced synaptic dopamnie concentrations: evidence from a novel positron emission tomography method,” . Proceedings National Academy of Science , 94 : 2569 – 2574 .
   PubMed Web of Science ®Google Scholar
• Bremner , J.D. , Innis , R.B. , Ng , C.K. , Staib , L.H. , Salomon , R.M. , Bronen , R.A. , Duncan , J. , Soutwick , S.M. , Krystal , J.H. , Rich , D. , Zubal , G. , Dey , H. , Soufer , R. and Chamey , D.S. 1997 . “Positron emission tomography measurement of cerebral metabolic correlates of Yohimbine administration in combat‐related posttraumatic stress disorder,” . Archives of General Psychiatry , 54 : 246 – 254 .
   PubMed Web of Science ®Google Scholar
• Bremner , J.D. , Innis , R.B. , Salomon , R.M. , Staib , L.H. , Ng , C.K. , Miller , H.L. , Bronin , R.A. , Krystal , J.H. , Duncan , J. , Rich , D. , Price , L.H. , Malison , R. , Dey , H , Soufer , R. and Charney , D.S. 1997 . “Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion‐induced depressive relapse,” . Archives of General Psychiatry , 54 : 364 – 374 .
   PubMed Web of Science ®Google Scholar
• Chamey , D.S. , Woods , S.W. , Krystal , J.H. , Nagy , L.M. and Heninger , G.R. 1992 . “Noradrenergic neuronal dysregulation in panic disroder: the effects of intravenous yohimbine and clonidine in panic disorder patients,” . Acta Psychiatry Scandinavia , 86 : 273 – 282 .
   Google Scholar
• Daniel , D.G. , Weinberger , D.R. , Jones , D.W. , Zigun , J.R. , Coppola , R. , Handel , S. , Bigelow , L.B. , Goldberg , T.E. , Berman , K.F. and Kleinman , J.E. 1991 . “The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia,” . Journal of Neuroscience , 148 : 78 – 84 .
   Google Scholar
• Delgado , P.L. , Price , L.H. Miller , H.L. 1991 . “Rapid serotonin depletion as a provocative challenge test for patients with major depression: Relevance to antidepressant action and the neurobiology of depression,” . Psychopharmacology Bulletin , 27 : 321 – 330 .
   PubMedGoogle Scholar
• Delgado , P.L. , Price , L.H. , Miller , H.L. , Salomon , R.M. , Aghajanian , G.K. , Heninger , G.R. and Charney , D.S. 1994 . “Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug‐free depressed patients,” . Archives of General Psychiatry , 51 : 865 – 874 .
   PubMed Web of Science ®Google Scholar
• Goodwin , F.K. 1971 . “Psychiatric side effects of Levodopa in man,” . Journal of the American Medical Association , 218 Dec. 27 : 1915 – 1920 .
   PubMed Web of Science ®Google Scholar
• Gorman , J.M. , Fyer , M.R. , Liebowitz , M.R. and Klein , D.F. 1997 . “Pharmacologic provocation of panic attacks,” . In Psychopharmacology: The Third Generation of Progress, , Edited by: Meltzer , HY . NY : Raven Press .
   Google Scholar
• Hollander , E. , DeCaria , C.M. , Nitescu , A. , Gully , R. , Suckow , R.F. , Cooper , T.B. , Gorman , J.M. , Klein , D.F. and Liebowitz , M.R . “Serotonergic functions in obsessive‐compulsive disorder: behavioral and neuroendocrine responses to oral m‐chlorophenylpiperazine and fenfluramine in patients and healthy volunteers,” . Archives of General Psychiatry , 49 21 – 8 .
   Google Scholar
• Hollister , L.E. 1981 . “Experiences with dopamine agonists in depression and schizophrenia,” . Apomorphine and Other Dopaminomimetics, Vol. 2: Clinical Pharmacology , : 57 – 64 .
   Google Scholar
• Iqbal , N. , Asnis , G.M. , Wetzler , S. , Kahn , R.S. , Kay , S.R. and van Praag , H.M. 1991 . “The MCPP challenge test in schizophrenia: hormonal and behavioral responses,” . Biological Psychiatry , 30 : 770 – 778 .
   Web of Science ®Google Scholar
• Jody , D. , Lieberman , J.A. , Geisler , S. , Szymanski , S. and Alvir , J.M. 1990 . “Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia,” . Psychopharmacological Bull , 26 : 224 – 230 .
   PubMed Web of Science ®Google Scholar
• Kahn , R.S. , Siever , L. , Davidson , M. , Gabriel , S. , Amin , F. , Stem , R.G. , DuMont , K. , Apter , S. and Davidson , M. 1992 . “Serotonin function in schizophrenia: effects of meta‐chlorophenylpiperazine in schizophrenic patients and healthy subjects,” . Psychiatry Research , 43 : 1 – 12 .
   Google Scholar
• Koreen , A.R. , Lieberman , J.A. , Alvir , J. and Chakos , M. 1992 . “The behavioral effect of m‐chlorophenylpiperazine (mCPP) and methylphenidate in first episode schizophrenia and normal controls,” . Neuropsychopharmacology , 16 : 61 – 68 .
   Google Scholar
• Kirpatrick , B. , Carpenter , W.T. , Buchanan , R.W. , Breier , A. and Tamminga , C.A. 1992 . “Plasma prolactin as a predictor of relapse in drug‐free schizophrenic outpatients,” . Biological Psychiatry , 32 : 1049 – 1054 .
   Google Scholar
• Krystal , J.H. , Seibyl , J.P. , Price , L.H. , Woods , S.W. , Heninger , G.R , Aghajanian , G.K. and Chamey , D.S. 1993 . “m‐Chlorophenylpiperazine effects in neurolepticfree schizophrenic patients: Evidence implicating serotonergic systems in the positive symptoms of schizophrenia,” . Archives of General Psychiatry , 50 : 624 – 635 .
   Google Scholar
• Lahti , A.C. , Koffel , B. , LaPorte , D. and Tamminga , C.A. 1995 . “Subanesthetic doses of ketamine stimulate psychosis in schizophrenia . "Neurpsychopharmacology , 13 : 9 – 19 .
   PubMed Web of Science ®Google Scholar
• Laruelle , M. , Ab‐Dargham , A. , van Dyck , C.H. , Gil , R , D'Souza , C.D. , Erdos , J. , McCance , E. , Rosenblatt , W. , Fingado , C. , Zoghbi , S.S. , Baldwin , R.M. , Seibyl , J.P. , Krystal , J.H. and Chamey , D.S. 1996 . “Single photon emission computerized tomography imaging of amphetamine‐induced dopamine release in drug‐free schizophrenic subjects,” . Proceedings National Academy of Science , August : 9235 – 9240 .
   Google Scholar
• Lieberman , J.A. , Kane , J.M. Gadaleta , D. 1984 . “Methylphenidate challenge as predictor of relapse in schizophrenia,” . American Journal of Psychiatry , 141 : 633 – 638 .
   PubMed Web of Science ®Google Scholar
• Lieberman , J.A. , Kane , J.M. and Alvir , J. 1987 . “Provocative tests with psychostimulant drugs in schizophrenia,” . Psychopharmacology , 91 : 415 – 433 .
   PubMed Web of Science ®Google Scholar
• Lieberman , J.A. , Alvir , J. , Geisler , S. , Ramos‐Lorenzi , J. , Werner , M. , Novaccenko , H. , Cooper , T. and Kane , J.M. 1994 . “Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia,” . Neuropsychopharmacology , 1994 ( 11 ) : 107 – 118 .
   Google Scholar
• Mezzacappa , E. , Steingard , R. , Kindlon , D. , Saul , J.P. and Earls , F. 1998 . “Tricyclic antidepressants and cardiac autonomic control in children and adolescents,” . Journal of the American Academy of Child and Adolescent Psychiatry , 37 : 52 – 9 .
   Google Scholar
• Mathew , R.J. and Wilson , W.H. 1989 . “Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients,” . Neuropsychobiology , 21 : 117 – 123 .
   Google Scholar
• Morello , M. , Starkstein , S. , Petracca , G. , Cataneo , E. A. , Manes , F. and Leiguarda , R. 1996 . “Drug‐induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L‐Dopa and apomorphine,” . Clinical Neuropharmacology , 19 : 439 – 443 .
   Google Scholar
• Perovich , R.M. , Lieberman , J.A. , Fleishhacker , W.W. and Alvir , J. 1989 . “The behavioral toxicity of bromocriptine in patients with psychiatric illness,” . Journal of Clinical Psychopharmacology , 9 : 417 – 422 .
   Google Scholar
• Sanfilipo , M. , Wolkin , A. , Angrist , B. , van Kammen , D.P. , Duncan , E. , Wieland , S. and Cooper , T.B. 1996 . “Amphetamine and negative symptoms of schizophrenia,” . Psychopharmacology , 123 : 211 – 214 .
   Google Scholar
• Sharma , R.P. , Javaid , J.I. , Pandey , G.N. , Jainacak , P.G. and Davis , J.M. 1991 . “Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients,” . Biological Psych. , 30 : 459 – 166 .
   Google Scholar
• Southwick , S.M. , Krystal , J.H. , Bremner , D. , Morgan , C.A. III , Nicolaou , A.L. , Nagy , L.M. , Johnson , D.R. , Heninger , G.R. and Chamey , D. 1997 . “Noradrenergic and serotonergic function in posttraumatic stress disorder,” . Archives of General Psychiatry , 54 : 749 – 758 .
   PubMed Web of Science ®Google Scholar
• Strakowski , S.M. , Sax , K.W. , Setter , M.J. , Stanton , S.P. and Keck , P.E. Jr. 1997 . “Lack of enhanced response to repeated d‐amphetamine challenge in first‐episode psychosis: implications for a sensitization model of psychosis in humans,” . Biological Psychiatry , 42 : 749 – 755 .
   PubMed Web of Science ®Google Scholar
• van Kammen , D.P. , Bunney , W.E. Jr , Dochety , J.P. , Marder , S.R , Ebert , M.H. , Rosenblatt , J.E. and Rayner , J.N. 1982 . “d‐Amphetamine‐induced heterogenous changes in psychotic behavior in schizophrenia,” . American Journal of Psychiatry , 1982 ( 139 ) : 991 – 997 .
   Google Scholar
• van Kammen , D.P. , Dochety , J.P. , Marder , S.R. , Rosenblatt , J.E. and Bunney , W.E. 1985 . “Lithium attenuates the activation‐euphoria but not the psychosis induced by d‐amphetamine in schizophrenia,” . Psychopharmacology (Berl) , 87 : 111 – 115 .
   Google Scholar
• Wolkin , A. , Sanfilipo , M. , Angrist , B. , Duncan , E. , Wieland , S. , Wolf , A.P. , Rodie , J.D. , Cooper , T.B. , Laska , E. and Rotrosen , J.P. 1994 . “Acute d‐amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology,” . Biological Psychiatry , 36 : 317 – 325 .
   Google Scholar
• Miller , F.G. and Rosenstein , D.L. 1997 . [of NIMH], “Psychiatric symptom‐provoking studies: an ethical appraisal,” . Biological Psychiatry , 42 : 403 – 409 . Miller serves on NIMH's Institutional Review Board, Rosenstein is a research investigator at NIMH.
   PubMedGoogle Scholar
• National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research . 1979 . Report and Recommendations, (Belmont Report) , DHEW Publication No. (05) 78–0006 Washington D.C. : U.S. Dept. of HEW .
   Google Scholar
• Declaration of Helsinki TV, World Medical Association, 18th World Medical Assembly, 1964; amended Hong Kong, Sept, 1989.
   Google Scholar
• Advisory Committee on Human Radiation Experiments . 1995 . Final Report , Washington, D.C. : GPO #IND 072595‐A . Willowbrook: hepatitis experiments on mentally retarded children, 1950s‐1960s; Tuskegee:: syphilis experiment on African‐American men, 1940s‐1972; Massachusetts Institute of Technology: radioactive iron/calcium given to retarded children, 1950–1953; Jewish Chronic Disease Hospital experiments injected live cancer cells into elderly patients, 1960s‐1970s; For a recitation and detailed description of these and other unethical human experiments in America, see:
   Google Scholar
• Shamoo , A.E. and Irving , D. 1993 . “Accountability in research using persons with mental illness,” . Accountability in Research , 3 : 1 – 17 .
   PubMedGoogle Scholar
• Bonnie , R.J. 1997 . “Research with cognitively impaired subjects: Unfinished business in the regulation of human research,” . Archives of General Psychiatry 1997 , 54 : 105 – 111 .
   PubMedGoogle Scholar
• Aller , Robert , Becker , Janice , Andrew , Mel , Brownstein , Muriel , Friend , Joseph , Guha , Arun , Nissin , Arliss , Post , Beverley , Prince , Shalmah Lee , Vukov , Judith and Sharav , Vera Hassner . 1997 . NBAC meeting . Sept. 18 1997 . Documented testimonies by victims, their families and Citizens for Responsible Care in Psychiatry and Research:
   Google Scholar
• Grady , Denise . 1999 . “Patient or Guinea Pig? Dilemma of Clinical Trials,” . NY Times , Jan 5 : C‐1
   Google Scholar
• Whitaker , R. and Kong , D. 1998 . “Doing Harm: Research on the mentally ill,” . The Boston Globe , Nov. 15–18 Front Page series,
   Google Scholar
• Goldman , D. 1943 . “Studies on the Use of Refrigeration Therapy in Mental Disease with Report of Sixteen Cases,” . Journal of Nervous and Mental Diseases , 97 : 152 – 165 .
   Google Scholar
• Library of Congress exhibit . 1998 . “Sigmund Freud: Conflict in Culture,” . Adapted from Karl Kraus, as cited at
   Google Scholar
• Shamoo , A.E. and Keay . 1996 . “Ethical concerns about relapse studies,” . Cambridge Quarterly of Health Care Ethics , 5 : 373 – 386 .
   PubMed Web of Science ®Google Scholar
• Gilbert , P.L. , Harris , M.J. McAddams , L.A. 1995 . “Neuroleptic withdrawal in schizophrenic patients,” . Archives of General Psychiatry , 52 : 173 – 186 .
   PubMed Web of Science ®Google Scholar
• Viguera , A.C. , Baldessarini , J.R. , Hegarty , J.D. , van Kammen , D.P. and Tohen , M. 1997 . “Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment,” . Archives of General Psychiatry , 54 : 49 – 55 .
   PubMed Web of Science ®Google Scholar
• Ricaurte , G.A. and McCann , U.D. 1992 . “Neurotoxic amphetamine analogues: effects in monkeys and implications for humans,” . Annals of NY Academy of Science , 648 : 371 – 82 . See also:
   PubMed Web of Science ®Google Scholar
• Ellison , G. 1995 . “The N‐methyl‐E‐asparate antagonists phencyladine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias . Brain Research , 20 : 250 – 267 .
   Google Scholar
• Javitt , D.C. and Zukin , S.R. 1991 . “Recent advances in the phencyclidine model of schizophrenia,” . American Journal of psychiatry , 148 : 1301 – 1308 .
   PubMed Web of Science ®Google Scholar
• McCann , U.D. , Seiden , L.S. , Rubin , L.J. and Ricaurte , G.A. 1997 . “Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine,” . JAMA , 278 Aug. 27 : 666 – 672 .
   PubMed Web of Science ®Google Scholar
• Olney , J.W. and Farber , N.B. 1995 . “NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia/’ . Neuropsychopharmacology , 13 : 335 – 345 . in Ellison [Ref. 88]
   PubMed Web of Science ®Google Scholar
• Robinson , T.E. and Becker , J.B. 1986 . “Enduring changes in brain and behavior produced by chronic amphetamine administration,” . Brain Research Reviews , 11 : 157 – 198 .
   Web of Science ®Google Scholar
• Sharp , F.R. , Butman , M , Aardalen , K. , Nickolenko , J. , Nakki , R. , Massa , S.M. and Swanson , R.A. 1994 . “Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics,” . Psychopharmacology Bulletin , 30 : 555 – 560 .
   PubMedGoogle Scholar
• Ikonamidou , C , Bosch , F. , Miksa , M. , Bittigau , P. , Vocker , J. , Dikranian , K. , Tenkova , T.I. , Stefovska , V. , Turski , L. and Olney , J.W. 1999 . “Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain,” . Science , 283 Jan. 1 : 70 – 74 .
   Google Scholar
• Tamminga , C , Holcomb , H.H. , Gao , X.‐M. and Lahti , A.C. 1995 . “Glutamate pharmacology and the treatment of schizophrenia: current status and future directions,” . International Clinical Psychopharmacology , 3 ( 10 Suppl. ) : 29 – 37 .
   Google Scholar
• Hilts , P.J. 1998 . “Psychiatric Research Under Fire,” “Do Consent Forms Tell Enough?” . NY Times , May 19 : C‐1
   Google Scholar
• Malhotra , A.K. , Pinals , D.A. , Adler , C.M. , Elman , I. , Clifton , A. , Pickar , D. and Breier , A. 1997 . “Ketamine‐induced exacerbation of psychotic symptoms and cognititve impariment in neuroleptic‐free schizophrenics,” . Neuropsychopharmacology , 17 : 141 – 150 .
   PubMed Web of Science ®Google Scholar
• Hassner [Sharav] , V. and Weisburd , D. 1994 . The Journal of the California Alliance of the Mentally Ill , Ethics in Neurobiological Research with Human Subjects, Co‐edited by
   Google Scholar
• Shamoo , A.E. , ed. 1997 . Ethics in Neurobiological Research with Human Subjects, Proceedings, , Gordon & Breach Pub. .
   Google Scholar
• Lehrman , N.S. and Sharav , V.H. “Ethical problems in psychiatric research,” . The Journal of Mental Health Administration , 1997 ( 24 ) 227 – 250 .
   Google Scholar
• Lehrman , N.S. “The ethics of harmful psychiatric research: a faulty effort to defend them,” . Accountability in Research , 1997 ( 5 ) 283 – 288 .
   Google Scholar
• Oral and written testimony was provided by Shamoo and Sharav—to NBAC, and several Congressional Committee Hearings [Gov. Reform & Oversight Committee, April 22,1998; Subcommittee on Human Resources [of Reform & Oversight], June 11, 1998].
   Google Scholar
• Under the National Animal Welfare Act, 1966, revised numerous times, a system of independent oversight and accountability protect laboratory animals. To ensure the AWA is enforced, the Animal & Plant Health Inspection Service (APHIS) of the USDA inspects the premises of regulated facilities and takes regulatory action against persons found to be in violation of the AWA regulations. In fiscal year 1997, a staff of about 73 Animal Care inspectors conducted almost 16,000 inspections to ensure compliance with the AWA regulations. No such inspections monitor the well‐being of human subjects of research.
   Google Scholar
• [See Ref 9] Among the documents presented to NBAC, is a court affidavit by the Chief of Psychiatry at the Bronx VA Medical Center, (re: Shalmah Lee Prince's lawsuit). It states: "it was the norm and practice of researchers and IRBs not to discuss any such risk [of drug washout] in consent forms...”;
   Google Scholar
• Published evidence of current, federally funded relapse inducing experiments [See Ref 3] were provided to NBAC. As if to underscore their disregard for compliance with human subject regulations, only 13 out of 100 protocols were sent to NBAC following this Presidential Commission's request to review 100 protocols and consent forms. And those reviewed failed to fully comply with current federal regulations.
   Google Scholar
• National Bioethics Advisory Commission, Transcript of meeting, Nov. 23,1997.
   Google Scholar
• The financial incentives—$470 million annually in NIMH grants and $10,000‐$35,000 per human subject in an industry sponsored drug trial—the competitive pressure to recruit as many subjects as possible, in order to get those grants, has increased the risks for vulnerable populations. [See Ref. 11, 48] Thus, the American College of Neruropsychopharmacology, whose members are the major beneficiaries of the symptom‐provocation experiments, adopted “A Statement of principles of ethical conduct for neuropsychopharmacologic research in human subjects,”; [by Klein D.F., Schooler, N.] Feb, 1996, giving its members permission to conduct experiments on incapacitaed psychiatric patients, [see, Lehrman, Sharav, Ref. 20].
   Google Scholar
• Antony M.M. et al. (1997). Bremner, J.D. et al. (1997). Charney, D.S. et al. (1992). Southwick, S.M. et al. (1997). [See Ref. 3].
   Google Scholar
• Kerr , K. 1997 . ‐Feb. 16, 1998, “Fen‐Phen Diet drug damaging the brain?/lawyers: confusion, aggression reported” . Newsday , Dec. 3 Evidence of neurotoxic brain damage in animal studies with fenfluramine was well known, even before its link to pulminary/heart damage was fully known. On Dec. 15, 1993, in a letter to the FDA, a group of prominent neuroscientists, led by Dr. George Ricaurte of Johns Hopkins warned about its potential danger in humans. That warning went unheeded. On Dec. 7, 1995 a group of 22 neuroscientists again implored the FDA in a letter not to approve it until its potential to cause neurological damage in humans was further examined. See,
   Google Scholar
• Coccaro , E.F. , Kavoussi , R.J. and Hauger , R.L. 1997 . “Serotonin function and antiaggressive response to fluoxetine: a pilot study,” . Biological Psychiatry , 1997 ( 42 ) : 546 – 52 .
   Google Scholar
• Halperin , J.M. 1997 . “Serotonin, aggression and parental psychopathology in children with attention deficit hyperactivity disorder . Journal of the American Academy of Child Adolescent Psychiatry , 36 : 1391 – 1398 .
   PubMed Web of Science ®Google Scholar
• Pine , D.S. , Coplan , J.D. , Wasserman , G.A. , Miller , L.S. , Fried , J.E. , Davies , M. , Cooper , T.B. , Greenhill , L. , Shaffer , D. and Parsons , B. 1997 . “Neuroendocrine response to fenfluramine challenge in boys,” . Archives of General Psychiatry , 54 : 839 – 846 .
   PubMed Web of Science ®Google Scholar
• Stoff , D.M. , Pasatiempo , A.P. , Yeung , J.H. , Bridger , W.H. and Rabinovich , H. 1992 . “Test‐retest reliability of the prolactin and cortisol responses to D,L‐fenfluramine challenge in disruptive behavior disorders,” . Psychiatry Research , 42 : 65 – 72 .
   Google Scholar
• Executive Order #12975 . 1995 . Federal Register , 60 (193) October 3 : 52063 – 52065 .
   Google Scholar
• Alexander Capron, PhD, Eric Cassell, MD, Alta Charo, Patricia Backlar, Diane Scott‐Jones, PhD: NBAC transcript, Nov. 23, 1997.
   Google Scholar
• Lieberman , J.A. , Sheitman , B.B. and Kinon , B.J. “Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronoal regulation and plasticity,” . Neuropsychopharmacology , 1997 ( 17 ) 205 – 229 .
   Google Scholar
• Lieberman , J.A. , Kane , J.M. and Alvir , J. 1987 . “Provocative tests with psychostimulant drugs in schizophrenia,” . Psychopharmacology , 91 : 1 – 5 . 1987,
   Google Scholar
• 31. Ellison, 1995; Javitt, 1991 [See, Ref. 15].
   Google Scholar
• Turner , D.M. “Ketamine: the ultimate psychedelic journey,” . The Essential Psychedelic Guide online, The Vaults of Erowid , http://www.erowid.org/ entheo_issues/writings/psychedelic_guide/ketamine.html.
   Google Scholar
• Kong , D. 1998 . “Drug studies are questioned,” . Boston Globe , Dec. 31 front page; [See also Ref. 16]
   Google Scholar
• Jansen , K.L.R. 1997 . “The Ketamine Model of the Near Death Experience: A Central Role for the NMDA Receptor,” . Journal of Near‐Death Studies , 16 ( 1 )
   Google Scholar
• Caldwell , C.B. and Gottesman II . 1992 . “Schizophrenia—a high‐risk factor for suicide: clues to risk reduction,” . Suicide and Life‐Threatening Behavior , 22 : 479 – 193 .
   PubMed Web of Science ®Google Scholar
• Shamoo , A.E. , Irving , D.N. and Langenberg , P. 1997 . “A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966–1993,” . Science and Engineering Ethics , 3 : 395 – 406 .
   PubMedGoogle Scholar
• American Psychiatric Association . 1997 . “Practice Guideline for the treatment of patients with schizophrenia,” . American Journal of Psychiatry Suppl , 154 : 63
   Google Scholar
• Wyatt , R.J. 1995 . “Neuroleptics and the natural course of schizophrenia,” . Schizophrenia Bulletin , 1991 ( 17 ) : 325 – 351 .
   Google Scholar
• Wyatt , R.J. “Risks of withdrawing anti‐psychotic medications,” . Archives of General Psychiatry , 52 205 – 208 .
   Google Scholar
• Janowsky , D.S. , El‐Yousef , D. , Davis , J.M. and Sekerke , H.J. 1973 . “Provocation of schizophrenic symptoms by intravenous administration of methylphenidate,” . Archives of General Psychiatry , 28 : 185 – 191 .
   PubMed Web of Science ®Google Scholar
• Laruelle (1996). [See Ref. 3].
   Google Scholar
• Strakowski et al. (1997). [See Ref. 3].
   Google Scholar
• Beauchamp , T.L. 1996 . “Looking back and judging our predecessors,” . Kennedy Institute of Ethics Journal , 6 : 251 – 270 .
   PubMed Web of Science ®Google Scholar
• U.S. Office of Protection from Research Risks . May 11 1994 . “ Evaluation of Human Subject Protection... UCLA ” . May 11 , Maryland Psychiatric Research Center . Letter of findings, April 16, 1998;
   Google Scholar
• U.S. General Accounting Office . 1996 . “Scientific Research: Continued Vigilance critical to protecting human subjects,” . In Report to the Senate Committee on Gov Affairs GAO/HEHS‐96–72
   Google Scholar
• U.S. Office of Instpector General . June 1998 . Report, Institutional Review Boards: A Time for Reform June , OEI‐01–97–00193.
   Google Scholar
• Angrist and Gershon, 1970; Goodwin, 1971; Hollister, 1981; van Kammen, 1982; Lieberman, 1987 [See Ref. 3].
   Google Scholar
• Jody, D. and Lieberman et al. (1990). [See Ref. 3].
   Google Scholar
• Lieberman et al. (1994). [See Ref. 3].
   Google Scholar
• Carpenter , W.T. , Schooler , N.R. and Kane , J.M. 1997 . “The rationale and ethics of medication‐free research in schizophrenia,” . Archives of General Psychiatry , 54 : 401 – 407 .
   PubMed Web of Science ®Google Scholar
• Applebaum , P.S. 1996 . “Drug‐free research in schizophrenia: An overview of the controversy,” . IRB: A Review of Human Subjects Research , 18 : 1 – 5 .
   Google Scholar
• Goodwin , F.K. and Hadley , S.W. 1994 . “Enhancing the climate of trust in clinical psychiatric research,” . Edited by: Shamoo . 253 – 263 . [See Ref. 25] Lieberman, J.A. et al. [See Ref 3].
   Google Scholar
• Kerr , K. 1998 . “Drug Study Questioned: All subjects in city test were minorities,” . NY Newsday , April 14 : A‐32 Reports in the press about harm to individuals:
   Google Scholar
• Hilts , P. 1998 . “Experiments On Children Are Reviewed,” . NY Times , April 15 : B‐1
   Google Scholar
• Montero , D. 1998 . “Did City Hosps Jeopardize Kids to Conduct Research?” . NY Post , April 14 : 4 on‐going follow‐up
   Google Scholar
• Wadman , M. 1998 . “Row erupts over child aggression study,” . Nature , April : 747
   Google Scholar
• Schoofs , M. 1998 . “Did Doctors Mislead the parents of Kids the Experimented On?” . Village Voice , May 5
   Google Scholar
• Weiss , R. 1998 . “Research Volunteers Unwittingly at Risk,” . Washington Post , Aug. 1 : A‐1
   Google Scholar
• Kerr , K. 1998 . “Informed Consent? Drug researchers criticized for involving psychiatric patients without fully explaining the risks,” . NY Newsday , Sept. 8 : C‐6 – 7 .
   Google Scholar
• Davis , R. “U.S. Human Medial Tests Lack Oversight,” . USA Today , front page
   Google Scholar
• Wadman , M. 1998 . “Research Roulette” . CityPaper , July 1
   Google Scholar
• Birnbaum , G. 1999 . “Science or Abuse? State Testing Prozac on 6‐Year Olds,” . NY Post , Jan. 31 : 7 – 8 .
   Google Scholar
• Strassman , R.J. 1995 . “Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects,” . Journal of Nervous Diseases , 183 : 127 – 138 .
   PubMed Web of Science ®Google Scholar
• Center Watch, Inc. “An Investigator's Guide to Clinical Research,” . monthly/ weekly , “CRO Directory”; & Internet Clinical Trial Listing Service, Boston, MA
   Google Scholar
• Stecklow , S. and Johannes , L. 1997 . ‘Test Case: Drug Makers Relied on Clinical Researchers Who Now Await Trial—Two Professors Are Accused of Endangering Patients And Stealing $10 Million,” . The Wall Street Journal , August 15 front page
   Google Scholar
• Miller , F. “Comments on the second report of the Maryland Attorney General's Research Working Group,” . Journal of Health Care Law & Policy , 1 193 – 202 .
   Google Scholar
• Capron [See Ref. 27].
   Google Scholar
• Davidson , M. , Keefe , R.S.E. Mohs , R.C. 1987 . “L‐Dopa challenge and relapse in schizophrenia,” . American Journal of Psychiatry , 144 : 934 – 938 .
   PubMed Web of Science ®Google Scholar
• Sharav , Hassner . 1994 . “What's ethical, what's not, where do you draw the line?” . L‐dopa consent form obtained under Freedom of Information is in author's file Concerns about this experiment were discussed previously: see, Lehrman and Sharav, 1997 [See Ref. 19];
   Google Scholar
• Miller and Rosentstein, 1997, found it especially troubling ethically. [See Ref. 2].
   Google Scholar
• The transcript was downloaded in June, 1997 from NBAC's website by an investigative reporter for the Boston Globe. When he attempted to retrieve a section that he had accidentally erased, the transcript was no longer available on NBAC's website. After public protests by Citizens for Responsible Care & Research, the transcript reappeared.
   Google Scholar
• A Sept 2, 1998 letter from OPRR to Andrew Brownstein, a former research subject at NIMH, confirmed that: “OPRR has completed its evaluation of human subject protections,”; and “NIMH has taken the following corrective actions...”;: “ensuring that subjects sign only one copy of an informed consent document...”; “Provision of a reminder to NIMH investigators of their responsibilities in regard to documentation of informed consent and assessment of decisional capacity of research subjects.”;
   Google Scholar
• 1999 . “Human Subject Protection Under Multiple Assurance (MPA) M‐1155, Research Projects Involving Human Subjects with Schizophrenia,” . January 18 U.S. DHHS, Office of Protection from Research Risks, Letter of Finding, Re: Citing the Code of Federal Regulations, OPRR's letter states: “OPRR finds that informed consent documents . . . . failed to include the following elements required by Department of Health and Human Services regulations at 45 CFR 46.116”;
   Google Scholar
• “An explanation of the purposes of the research; a complete and accurate description of the procedures (i.e., . . . the plan for a 4‐week washout period prior to sinemet [L‐dopa] challenge; the plan to withhold neuroleptic medication for up to one year or until relapse);
   Google Scholar
• An adequate description of all reasonably foreseeable risks and discomforts to the subject (i.e., the risk of schizophrenic relapse from either sinemet challenge or withdrawal of neuroleptic agents for up to one year, as well as the potential psychiatric, physical, social, and legal effects of such relapse; the psychological stress and anxiety. . . ; all the known major side effects of haldol, sinemet (L‐dopa) and selegiline, as well as possible adverse effects resulting from interactions of these medications”;
   Google Scholar
• “A description of appropriate alternative procedures or courses of treatment that might be advantageous to the subject . . .”;
   Google Scholar
• OPRR also found that “the MSSM IRB lacked sufficient information to make the determinations required for approval of research under HHS regulations”; and “failed to conduct continuing review"—as required under the Code of Federal Regulations.
   Google Scholar
• OPRR's findings—at UCLA, Maryland Psychiatric Research Center, Mount Sinai Medical Center—demonstrate serious ethical violations‐including failure to disclose relevant risks, thereby invalidating the informed consent obtained. Despite such repeated findings, and despite widespread criticism in the press no investigator or institution has been held accountable, no actions or even a reprimand were issued. [See Katz, 1993, Ref. 2; Shamoo and Irving, 1993, Ref. 8; Hassner [Sharav], 1994, Lehrman and Sharav, 1997, Ref. 20; Victim Testimonies, 1997, Ref. 9].
   Google Scholar
• Hilts , P. NY Times , Ref. 17;
   Google Scholar
• Borr , J. 1998 . “Mental patients at risk in research,” . Baltimore Sun , June 7 front page
   Google Scholar
• Wadman , M. 1998 . “Research Roulette: Are the Maryland Psychiatric Research Center's Schizophrenia Studies Harming Patients?” . CityPaper , July 1 cover story; St. Louis Post Dispatch, Editorial 1998;
   Google Scholar
• Whitaker and Kong . 1998 . “Doing Harm: Research on the Mentally Ill,” . Boston Globe , Nov. 15–18 front page] [See also Ref. 46]
   Google Scholar
• Dr. William Carpenter, Director, and Dr. Carol Tamminga, Deputy Director of MPRC were honored this year by the IOM. They, and James Childress, chairman of NBAC's human subjects sub‐committee, were inducted as new IOM members.
   Google Scholar
• Bowdie , T.A. , Radant , A.D. , Cowley , D.S. , Kharasch , E.D. , Strassman , R.J. and Roy‐Byrne , P.P. 1998 . “Psychedelic effects of ketamine in healthy volunteers,” . Anesthesiology , 88 : 82 – 88 .
   Google Scholar
• Cohen , S. 1960 . “Lysergic acid diethylamide: side effects and complications,” . Journal of Nervous Mental Diseases , 130 : 30 – 40 .
   PubMed Web of Science ®Google Scholar
• Kurland , A.A. , Yensen , R. and Dryer , D.A. “The relationship between peak experience and outcome in LSD assisted psychostherapy with substance abusers,” . a current project at the Orenda Institute, University of Maryland www.maps.org/ news
   Google Scholar
• Prospectus, Heffter Research Institute, West Lafayette, Indiana, online at: www.well.com/user/dpd/heffter.html (www.well.com/user/dpd/heffter.html)
   Google Scholar
• Geyer , M.A. 1998 . “Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research,” . Pharmacopsychiatry , 2 ( Suppl. ) July 31 : 73 – 79 .
   Google Scholar
• Krystal , J.H. , Petrakis , I.L. , Webb , E. , Cooney , N.L. , Karper , L.P. , Namanworth , S. , Stetson , P. , Trevisan , L.A. and Charney , D.S. 1998 . “Dose‐related ethanol‐like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics,” . Archives of General Psychiatry , 55 : 354 – 360 .
   PubMed Web of Science ®Google Scholar
• Schwartz , R.H. and Miller , N.S. 1997 . “MDMA (Ecstasy) and the Rave: A Review,” . Pediatrics , 100 : 705 – 708 .
   PubMed Web of Science ®Google Scholar
• Ricaurte , G.A. 1989 . “Studies of MDMA‐induced neurotoxicity in nonhuman primates: a basis for evaluating long‐term effects in humans,” . In Pharmacology and toxicology of amphetamines and related designer drugs , NIDA Res. Monogr. Edited by: Asghar , K. and DeSouza , E. Vol. 94 , 306 – 22 .
   Google Scholar
• Ricaurte , G.A. and McCann , U.D. 1992 . “Neurotoxic amphetamine analogues: effects in monkeys and implications for humans,” . Annals of the NY Academy of Sciences , 648 : 371 – 382 .
   PubMed Web of Science ®Google Scholar
• McCann , U.D. , Szbo , Z. , Scheffel , U. , Dannals , R.F. and Ricaurte , G.A. 1998 . “Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings,” . Lancet , 352 : 1433 – 1437 .
   PubMed Web of Science ®Google Scholar
• Morris and Kelly . 1998 . “Ecstasy users face consequences of neurotoxicity,” . Lancet , 352 Dec. 12 1913.
   Google Scholar
• Editorial . 1996 . “Walking on the moon,” . Lancet , 347 : 207
   Google Scholar
• Grob , C.S. , Poland , R.E. , Chang , L. and Ernst , T. 1996 . “Psychobiologic effects of 3,4‐methylenedioxymsethamphetamine in humans: methodological considerations and preliminary observations,” . Behavioral Brain Research 1996 , 73 : 103 – 107 . Updated information about this project is available on websites of the Hefter Institute and the Multidisciplinary Association of Psychedelic Studies, www.
   PubMed Web of Science ®Google Scholar
• Editorial . 1998 . St. Louis Post Dispatch , May
   Google Scholar
• Editorial . 1998 . The Boston Globe , Nov. 18
   Google Scholar
• Marshall , Elliot . 1999 . “NIMH to screen studies for science and human risks,” . Science , Jan. 22 : 464 – 165 .
   Google Scholar
• Hilts , P. 1999 . “Federal Reviews Are Urged for Experiments on Mental Patients,” . The NY Times , Feb. 4 : A‐22
   Google Scholar